MedTrace Logo

Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals

NCT04490824 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-10-04

No results posted yet for this study

Summary

Preliminary reports have been received from several sources that the periodic inhaling of the nebulized mist from water that has a heightened level of kinetic activity has quickly (less than 2 days) lessened the severity of symptoms in Covid-19 infected patients. On at least several occasions, a repeat PCR test performed several after inhaling a particular water-based product was negative. There are no perceived adverse effects from inhaling the water mist by using a nebulizer or humidifier. It is important, however, to validate these preliminary findings and to include the inhaling of the mist from water, which does not have an elevated level of kinetic activity. This will be by performed in a patient-blinded manner by sequentially inhaling the two types of water over consecutive 2-day periods with Covid-19 testing at the end of each of the two day periods. Participants will be randomized as to whether they are to inhale the mist from the test or the control water.

Conditions

  • Covid19

Interventions

DEVICE

KELEA Excellerated Water

Water with increased kinetic activity as assessed by published methods of the PI

DEVICE

Water Without an Elevated Level of KELEA

Bottled water without an elevated level of KELEA, as shown by proprietary testing will be provided as a control.

Sponsors & Collaborators

  • Institute of Progressive Medicine

    lead OTHER

Principal Investigators

  • W John Martin, MD, PhD · Medical Director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2023-12-31
Completion
2024-03-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04490824 on ClinicalTrials.gov